Compare Bristol-Myers Squibb Co (BMY) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Veritone Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Veritone Inc trades at $1.55 (market cap $138.04M). The key difference: Bristol-Myers Squibb Co is far larger — about 941.3× Veritone Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| BMY | VERI | |
|---|---|---|
Market Cap | $129.94B | $138.04M |
Sector | Health | Technology |
52-Week High | $65.89 | $8.39 |
52-Week Low | $42.60 | $1.00 |
Enterprise Value | $163.92B | $170.07M |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Veritone (VERI) trades at $1.52, up 5.56% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $111.73 million in 2025, with a negative net income margin of -123.76%, though revenue remains around $90-92 million. Recent news highlights partnerships in AI and public safety, but the stock faces headwinds from a securities class action lawsuit with a July 20, 2026 deadline.
The outlook is mixed: analyst consensus is evenly split between Buy and Hold ratings, but persistent losses and legal risks overshadow growth initiatives. Investment opportunity hinges on Veritone's ability to monetize its AI solutions and achieve profitability, while key risks include ongoing litigation and competitive pressures in the enterprise AI space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
